Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19339818 | 0.91 | LMNA (0.55) | LMNAPRNPMEN1KMT2AALDH1A1 | |
| SCHEMBL4828442 | 0.81 | NPC1 (0.59) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL27871000 | 0.78 | KMT2A (0.61) | LMNAPRNPMEN1KMT2AAHR | |
| SCHEMBL7603312 | 0.77 | NPC1 (0.50) | PRNPMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4828397 | 0.77 | LMNA (0.44) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4519224 | 0.76 | PTPN1 (0.65) | LMNAPRNPMEN1KMT2AAHR | |
| SCHEMBL4837018 | 0.76 | PRNP (0.54) | LMNAPRNPMEN1KMT2AAHR | |
| SCHEMBL30530505 | 0.76 | KMT2A (0.59) | PRNPMEN1KMT2AAHRALDH1A1 | |
| SCHEMBL1294284 | 0.76 | KMT2A (0.59) | PRNPMEN1KMT2AAHRALDH1A1 | |
| SCHEMBL14065383 | 0.75 | LMNA (0.55) | LMNAMEN1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| CN-1633291-A | 2-oxazolamines and their use as 5-HT2BUse of receptor antagonists | PHARMAGENE LAB LTD (GB) | 2005-06-29 | — | — | CN | disclosed |
| EP-1474140-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003068226-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | LMNA 4134/4885PRNP 2489/4885MEN1 3602/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | LMNA 3528/4885PRNP 3232/4885MEN1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.